Researchers have developed a new non-invasive test to detect endometrial cancer using cervical cells collected during a routine Pap smear. The method analyzes DNA methylation changes and focuses on three gene markers—ZNF626, GRIA4, and SPDYA.
The test, called MATS, showed strong performance in validation studies, achieving about 95% sensitivity and 90% specificity. It also detected more than 92% of early-stage (Stage I) cancers, and one marker helped distinguish endometrial cancer from other gynecologic cancers.
Because the test uses standard cervical samples, it could help doctors screen patients more easily and reduce the need for invasive diagnostic procedures such as hysteroscopy or biopsy.